Table 5.
Trial | Phase | Treatment | MSI/MSS status | N° patients | ORR (%) | PFS | OS |
---|---|---|---|---|---|---|---|
KEYNOTE 016
Le 2015 |
II | Pembrolizumab | Refractory MSI high mCRC Refractory MSS mCRC |
41(32 mCRC) | 40 0 |
NR 2.2 months |
NR 5 months |
KEYNOTE 164 | II | Pembrolizumab | Refractory MSI mCRC | 63 | 32 | 4.1 | 76% (12m) |
NCT02375672 | II | Pembrolizumab + FOLFOX | 1° line mCRC (3% MSI) | 30 | 53 | ||
Checkmate 142 | II | Nivolumab Nivolumab+ ipilimumab |
Refractory MSI mCRC | 74 119 |
31.1 55 |
50% (12 months) 71% (12 months) |
73% (12 months) 85% (12 months) |
COTEZO IMblaze370 | III | Atezolizumab versus
cobimetinib/atezolizumab versus regorafenib |
Refractory MSS and MSI mCRC | 90 183 90 |
- 2.7 - |
- | 7.1 8.87 8.5 |
CCTG CO.26 | Durvalumab/tramelimumab versus BSC | Refractory MSS mCRC | 6.6 versus 4.1 p = 0.07 |
||||
REGONIVO | Ib | Regorafenib + nivolumab | 33% MSS mCRC | 36 | |||
NCT02860546 | II | TAS102 + nivolumab | MSS mCRC | 18 | 0 | 2.8 |
mCRC, metastatic colorectal cancer; mOS, median overall survival; mPFS, median progression free survival; MSI, microsatellite instability; MSS, microsatellite stability; ORR, overall response rate.